APP Pharmaceuticals, a manufacturer of multi-source and branded injectable pharmaceutical products, has reported net revenues of $148.1 million for the first quarter of 2008, an increase of 6%, compared with $140.3 million in the first quarter of 2007.
Subscribe to our email newsletter
Gross profit was $70.1 million, or 47% of net revenues for the first quarter of 2008, compared with $65.4 million, or 47% of net revenues, in the first quarter of 2007.
Income from operations before interest expense for the 2008 first quarter increased by 11% to $32.5 million compared with $29.2 million in the 2007 first quarter. As a result of increased net interest expense, net income for the quarter was $9.2 million, or $0.06 per diluted share, versus first quarter 2007 net income of $11.1 million, or $0.07 per diluted share, which includes a loss from discontinued operations of $2.5 million, or $0.02 per share.
Tom Silberg, APP Pharmaceuticals’s president and CEO, said: “We expect that our strong core business, combined with recently introduced and anticipated new product launches, should contribute to continued revenue and earnings growth throughout the balance of the year.”
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.